Wells Fargo
DYN icon

Wells Fargo’s Dyne Therapeutics DYN Stock Holding History

Wells Fargo’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.64M Sell
145,509
-2,322
-2% -$40K ﹤0.01% 3060
2025
Q4 		$2.89M Buy
147,831
+60,710
+70% +$1.15M ﹤0.01% 3145
2025
Q3 		$1.1M Buy
87,121
+30,416
+54% +$347K ﹤0.01% 3744
2025
Q2 		$540K Buy
56,705
+16,547
+41% +$182K ﹤0.01% 4084
2025
Q1 		$420K Buy
40,158
+1,404
+4% +$20.1K ﹤0.01% 4222
2024
Q4 		$913K Buy
38,754
+13,677
+55% +$405K ﹤0.01% 3774
2024
Q3 		$901K Sell
25,077
-983
-4% -$39.1K ﹤0.01% 3612
2024
Q2 		$920K Buy
26,060
+6,103
+31% +$177K ﹤0.01% 3555
2024
Q1 		$567K Buy
19,957
+6,928
+53% +$157K ﹤0.01% 3806
2023
Q4 		$173K Sell
13,029
-22,217
-63% -$217K ﹤0.01% 4547
2023
Q3 		$316K Sell
35,246
-1,070
-3% -$11.5K ﹤0.01% 4055
2023
Q2 		$409K Buy
36,316
+30,469
+521% +$359K ﹤0.01% 4102
2023
Q1 		$67.4K Buy
+5,847
New +$75.9K ﹤0.01% 5004
2022
Q4 		– Sell
-41
Closed -$1K – 7521
2022
Q3 		$1K Sell
41
-315
-88% -$3.61K ﹤0.01% 6317
2022
Q2 		$2K Sell
356
-1,017
-74% -$7.01K ﹤0.01% 6305
2022
Q1 		$13K Sell
1,373
-10,672
-89% -$90.9K ﹤0.01% 6170
2021
Q4 		$144K Buy
+12,045
New +$169K ﹤0.01% 5445
2021
Q3 		– Sell
-323
Closed -$7K – 7053
2021
Q2 		$7K Sell
323
-4,726
-94% -$88.9K ﹤0.01% 6231
2021
Q1 		$78K Sell
5,049
-2,340
-32% -$45.3K ﹤0.01% 5595
2020
Q4 		$155K Buy
+7,389
New +$146K ﹤0.01% 5187

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Wells Fargo's DYN Position: Q1 2026 in Review

Wells Fargo reduced its Dyne Therapeutics (DYN) stake by 1.6% in Q1 2026, selling an estimated $40K and leaving 145,509 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Wells Fargo first reported a position in DYN in Q4 2020 and has held it in 20 quarters since. The position peaked at $2.89M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Wells Fargo held 145,509 shares of Dyne Therapeutics worth $2.64M as of Q1 2026.
  • Wells Fargo sold 2,322 Dyne Therapeutics shares in Q1 2026, an estimated $40K.
  • Dyne Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3060 holding.
  • Wells Fargo first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Wells Fargo's Dyne Therapeutics position peaked at $2.89M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.